| Title |
New developments in the management of hepatitis C virus infection: focus on boceprevir
|
|---|---|
| Published in |
Biologics: Targets & Therapy, August 2012
|
| DOI | 10.2147/btt.s24413 |
| Pubmed ID | |
| Authors |
Marina Berenguer, F Xavier López-Labrador |
| Abstract |
Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%-50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 12 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 17% |
| Student > Ph. D. Student | 2 | 17% |
| Professor > Associate Professor | 2 | 17% |
| Student > Master | 2 | 17% |
| Librarian | 1 | 8% |
| Other | 3 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 33% |
| Agricultural and Biological Sciences | 3 | 25% |
| Nursing and Health Professions | 1 | 8% |
| Immunology and Microbiology | 1 | 8% |
| Computer Science | 1 | 8% |
| Other | 2 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2015.
All research outputs
#4,711,216
of 25,584,565 outputs
Outputs from Biologics: Targets & Therapy
#53
of 274 outputs
Outputs of similar age
#31,576
of 179,468 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 10 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,468 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.